Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments

Kleijnen, Sarah; Fathallah, Mohammed; Linden, M.W. van der; Vancraeynest, Piet; Dahmani, Bachir; Timoney, Angela; Boer, Anthonius de; Leufkens, H.G.M.; Goettsch, Wim

doi:10.1016/j.jval.2015.03.1790

Cited by 8 publications

(9 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 9 domains of the HTA Core Model developed by EUnetHTA [44] For each domain of the Core Model, joint HTA work and local adaptation are both being considered. In line with previously discussed considerations, results in some domains are almost fully transferable, such as assessment of clinical effectiveness [47], while other domains have limited transferability, e.g. costs and economic evaluation.…”

Section: Article Highlightssupporting

confidence: 72%

The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries

Németh¹,

Goettsch

Kristensen

et al. 2020

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Introduction: Lower income European countries have a worse health status and less funds for health care compared to Western Europe. Despite their limited human and financial capacities for conducting Health Technology Assessment (HTA), the need for evidence-based decision-making is growing. Two main approaches emerged as potential solutions: joint clinical assessments on the European level, and simplified procedures relying on the judgements of well-established HTA agencies of Western countries.

show abstract

Section: Article Highlightssupporting

confidence: 72%

The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries

Németh¹,

Goettsch

Kristensen

et al. 2020

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…The establishment of the CDR in Canada has demonstrated a successful working model for sharing HTA evidence derived from a centralized review, to provide a more efficient use of resources to support regional decision making (Allen et al, 2016) Similarly, there is a general acceptance that decision making should remain at the national/local level in Europe, but this does not prevent collaborations for assessment (Kleijnen et al, 2015). The rationale underpinning the establishment of EUnetHTA has similarities with the rationale for the creation of the CDR, as both aim to reduce duplication of work, use HTA resources more efficiently, and provide access to robust scientific evidence.…”

Section: Discussionmentioning

confidence: 99%

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?

et al. 2017

View full text Add to dashboard Cite

Introduction: In Europe and beyond, the rising costs of healthcare and limited healthcare resources have resulted in the implementation of health technology assessment (HTA) to inform health policy and reimbursement decision-making. European legislation has provided a harmonized route for the regulatory process with the European Medicines Agency, but reimbursement decision-making still remains the responsibility of each country. There is a recognized need to move toward a more objective and collaborative reimbursement environment for new medicines in Europe. Therefore, the aim of this study was to objectively assess and compare the national reimbursement recommendations of 9 European jurisdictions following European Medicines Agency (EMA) recommendation for centralized marketing authorization.Methods: Using publicly available data and newly developed classification tools, this study appraised 9 European reimbursement systems by assessing HTA processes and the relationship between the regulatory, HTA and decision-making organizations. Each national HTA agency was classified according to two novel taxonomies. The System taxonomy, focuses on the position of the HTA agency within the national reimbursement system according to the relationship between the regulator, the HTA-performing agency, and the reimbursement decision-making coverage body. The HTA Process taxonomy distinguishes between the individual HTA agency's approach to economic and therapeutic evaluation and the inclusion of an independent appraisal step. The taxonomic groups were subsequently compared with national HTA recommendations.Results: This study identified European national reimbursement recommendations for 102 new active substances (NASs) approved by the EMA from 2008 to 2012. These reimbursement recommendations were compared using a novel classification tool and identified alignment between the organizational structure of reimbursement systems (System taxonomy) and HTA recommendations. However, there was less alignment between the HTA processes and recommendations.Conclusions: In order to move forward to a more harmonized HTA environment within Europe, it is first necessary to understand the variation in HTA practices within Europe. This study has identified alignment between HTA recommendations and the System taxonomy and one of the major implications of this study is that such alignment could support a more collaborative HTA environment in Europe.

show abstract

“…During EUnetHTA JA2, the value of the model and the capacity of HTA agencies to use the model and collaborate on production were shown. Experience from piloting the standardized structure, format, and methods shows that to realize added value for national (or regional) health authorities and manufacturers, some critical success factors for cross-border assessments are essential [24][25][26][27]. The most important issues that also increase the national uptake are selection of relevant topics and timing of assessments.…”

Section: Discussionmentioning

confidence: 99%

The HTA Core Model ® —10 Years of Developing an International Framework to Share Multidimensional Value Assessment

et al. 2017

View full text Add to dashboard Cite

show abstract

Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments

Cited by 8 publications

References 21 publications

The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries

The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?

The HTA Core Model ® —10 Years of Developing an International Framework to Share Multidimensional Value Assessment

Contact Info

Product

Resources

About